What is William Blair’s Estimate for APLS Q1 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at William Blair issued their Q1 2025 earnings per share estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Monday, October 28th. William Blair analyst L. Hanbury-Brown expects that the company will earn ($0.09) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS and Q3 2025 earnings at $0.13 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business had revenue of $199.70 million during the quarter, compared to the consensus estimate of $190.89 million. During the same quarter in the prior year, the company posted ($1.02) earnings per share. Apellis Pharmaceuticals’s revenue was up 110.2% compared to the same quarter last year.

Several other brokerages also recently issued reports on APLS. The Goldman Sachs Group upped their price target on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, August 9th. UBS Group decreased their price target on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. JPMorgan Chase & Co. decreased their price target on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Robert W. Baird reduced their price objective on Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, September 23rd. Finally, Wedbush raised their target price on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.41.

Apellis Pharmaceuticals Trading Down 1.6 %

Shares of Apellis Pharmaceuticals stock opened at $27.26 on Thursday. The stock has a fifty day simple moving average of $32.52 and a 200 day simple moving average of $37.94. Apellis Pharmaceuticals has a 12-month low of $26.28 and a 12-month high of $73.80. The company has a market capitalization of $3.31 billion, a P/E ratio of -7.88 and a beta of 0.87. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73.

Insider Buying and Selling

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Apellis Pharmaceuticals during the 1st quarter valued at about $89,000. nVerses Capital LLC grew its holdings in Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after buying an additional 2,100 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Apellis Pharmaceuticals by 1,300.8% during the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock valued at $211,000 after buying an additional 3,330 shares in the last quarter. CWM LLC grew its holdings in Apellis Pharmaceuticals by 299.9% during the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after buying an additional 3,113 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).